<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560700</url>
  </required_header>
  <id_info>
    <org_study_id>H-18011991</org_study_id>
    <nct_id>NCT03560700</nct_id>
  </id_info>
  <brief_title>Probiotic Efficacy in VRE Eradication</brief_title>
  <acronym>PROVE</acronym>
  <official_title>The Effect of a Lactobacillus Probiotic Strain on Eradication of Vancomycin Resistant Enterococcus Faecium (VRE) in Non-symptomatic VRE-carriers - a Multicenter, Randomized, Placebo-controlled, Parallel-group Study With 4 Weeks Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of a probiotic lactobacillus strain in eradicating VRE
      in non-symptomatic carriers after 4 weeks of treatment. It will also evaluate the long-term
      efficacy after 8,16 and 24 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the increased number of Vancomycin-Resistant Enterococcus faecium (VRE)
      infected/colonized people it is evident that new treatment options are needed to reduce the
      number of VRE cases. One such option could be to use probiotics. We hypothesize that
      treatment with a probiotic lactobacillus strain can reduce the number of VRE carriers
      significantly. The aim is to investigate if this strain can eradicate VRE in non-symptomatic
      VRE-carriers measured as the number of subjects without VRE colonization at week 4.

      This is a multi-center, randomized, double-blind, placebo-controlled parallel-group trial in
      non-symptomatic VRE-carriers.

      The Trial consists of a 4 weeks intervention period followed by a 20-week follow-up period.

      After patients have been confirmed as carriers of VRE, the subjects are randomized to 4
      weeks' treatment with a lactobacillus probiotic strain (60 billion CFU per day) or to
      placebo. Subjects' VRE carrier-state is assessed at weeks 4, 8, 16 and 24, by an in-house PCR
      analysis. Stool samples are collected before intervention (baseline) and at week 4, 8, 16 and
      week 24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with cleared VRE colonization at week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fecal sample diagnosed by pcr and detection of the vanA gene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of VRE colonization at week 8, 16 and 24 respectively</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Fecal sample diagnosed by pcr and detection of the vanA gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of VRE infections (isolation from non-intestinal foci)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbiota composition</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonization with probiotic lactobacillus strain</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>VRE Colonization</condition>
  <arm_group>
    <arm_group_label>lactobacillus probiotic strain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 billion CFU/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lactobacillus probiotic strain</intervention_name>
    <description>Approved Dietary supplement</description>
    <arm_group_label>lactobacillus probiotic strain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with VRE colonization (positive faecal swab)

          -  Subjects over 18 years of age

          -  Provided voluntary written informed consent

        Exclusion Criteria:

          -  Symptomatic VRE infection

          -  Serious immunodeficiency

          -  Pancreatitis

          -  Planned or recent intraabdominal operation within a time window of14 days)

          -  Parenteral nutrition

          -  Antibiotic treatment for VRE one month prior to inclusion

          -  Terminal disease with expected survival time &lt; 3 month

          -  Probiotic consumption within two weeks prior enrollment

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre Hospital, Copenhagen University</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas M Petersen, MD, ph.d</last_name>
      <phone>004538625960</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Maria Rubin, MD</last_name>
      <phone>004538625960</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas M Petersen, MD, ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Munk Petersen</investigator_full_name>
    <investigator_title>Md, Phd, Consultant</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

